Replies to post #23252 on Amarin Corp Plc (AMRN)

[David Fowler]

#1 is horseshit. You realize that this can still lose 100%? Therefore the loss from here wouldn't be minimal, it can be all of it.

[DeepBreath]

Thank you. David Fowler made the statement that the "FDA knows" this is snake oil and a scam. I am asking him the same question he posted awhile back....

Link or bullshit!!!

[sts66]

I bought some today and I based my decision on the following:

1) the SP is at a 3.5 year low; as a very famous banker/investor once said, buy when there's blood in the street.Because the SP is at a 3.5 year low, as long as you don't go crazy and bet the farm the downside is minimal, imo.

The blood in the street is there for a reason - AMRN is in big trouble for the moment, them's the facts. That said, if I didn't already own more shares than I should, I'd certainly take a flyer down here, but a smallish one. I bought in high, tried to avg down too high, now stuck where I am, too much dead money and very, very red - not going to throw more money at this to get my avg down even lower given the uncertainty of AMRN's success with the FDA.

2) the company has a staggering $226 million in cash; for a pharmaceutical co of this size this amount of cash is unheard of. Lots of cash means lots of opportunities.

VVUS had even more cash available when Q was approved, > $300M, and they only had 6 employees - but because of their forced GIA strategy (nobody wanted to partner to sell their poison) and onerous REMS program, plus horrendous sales, they will go bankrupt within 18 months unless they manage to raise more cash - they already did the same Pharmakon loan shark deal that AMRN did. That "lots of cash" can disappear in a hurry for a GIA company with slow sales - there are no "opportunities" for AMRN to use their cash but to pay for the sales force, who aren't earning their keep (yet).

3) my own DD. From everything I've read I think Amarin has a descent chance in having the FDA reconsider the ANCHOR SPA and possibly even approve Vascepa.

You mean approve the ANCHOR indication, I assume? Because Vascepa is already and FDA approved drug. I too believe AMRN has a decent chance at getting the SPA back in place, which likely leads to ANCHOR Adcom and PDUFA to correct the horrendous mistakes made at the first one.

4) other investors will see the same opportunity and so I believe you see buying over the next 2 weeks leading up to the Jan 15th FDA decision.

IMO, anyone who wants in on AMRN is probably in by now, and I doubt we see much of a run going into 1/15 - but if they get a favorable ruling, the pps should pop nicely, maybe to $3 or $4 - whether it stays there or drops back depends on more news. A bad ruling may drop it into the $1.50 range, which is ridiculously low - the stock is worth $1.30 on cash on hand alone.